PEB Pacific Edge Limited
—Mkt Cap: —P/E: —1d ago
Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. …
Industry Peers
Biotechnology$128.87BUSDP/E 29.6
$94.42BUSD
$81.99BUSDP/E 19.1
$53.47BUSDP/E 32.5
$53.22BUSDP/E 31.6
$44.02BUSDP/E 17.8
$42.56BUSDP/E 66.4
$40.57BUSD
$34.45BUSDP/E 30.4
$31.32BUSDP/E 39.3
$24.59BUSD
$23.32BUSDP/E 31.7
$23.26BUSDP/E 29.8
$22.96BUSDP/E 14.0
$22.66BUSD
$21.67BUSD
$15.57BUSDP/E 19.3
$14.91BUSDP/E 17.4
$13.92BUSDP/E 14.7
$13.79BUSDP/E 33.4
Key Statistics
Company
Market Cap—
Enterprise Value129.79M USD
Revenue (TTM)8.99M USD
Gross Profit7.95M USD
Net Income (TTM)-24.73M USD
Revenue/Share0.01 AUD
Last Price—
Fiscal Year EndMar 2026
MR QuarterMar 2026
Employees—
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINNZPEBE0002S1
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-5.29
EV/Revenue14.43
P/S18.13
P/B23.64
EPS (TTM)-0.03
EPS (Forward)—
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin100.00%
Oper. Margin-274.34%
EBITDA Margin-272.67%
Profit Margin-311.14%
ROE-335.66%
ROA-203.26%
Growth
Revenue Growth-45.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-22.07M USD
CapEx (TTM)91.22K USD
FCF Margin-147.26%
FCF Yield—
Net Debt-4.49M USD
Net Debt/EBITDA0.18
Balance Sheet
Debt/Equity0.12
Current Ratio2.02
Quick Ratio1.50
Book Value/Sh0.0080 AUD
Cash/Share0.0080 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.1.24B
Float853.81M
Insiders19.72%
Institutions30.16%
Technical
SMA 500.2087 AUD
SMA 2000.1961 AUD
Beta0.84
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)19.14K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—